Literature DB >> 17253727

Synthesis of fenthion sulfoxide and fenoxon sulfoxide enantiomers: effect of sulfur chirality on acetylcholinesterase activity.

Rama Sarma V S Gadepalli1, John M Rimoldi, Frank R Fronczek, Mae Nillos, Jay Gan, Xin Deng, Gabriela Rodriguez-Fuentes, Daniel Schlenk.   

Abstract

Earlier reports have demonstrated that recombinant flavin-containing monooxygenase 1 (FMO1) catalyzes the oxidation of the organophosphate pesticide fenthion to (+)-fenthion sulfoxide in a stereoselective fashion. In order to elucidate the absolute configuration of the sulfoxide metabolite produced, we established an efficient synthesis of both enantiomers of fenthion sulfoxide, which were transformed into chiral fenoxon sulfoxides using a two-step protocol. The use of chiral oxidants, namely, N-(phenylsulfonyl)(3,3-dichlorocamphoryl) oxaziridines, afforded enantioenriched fenthion sulfoxides with high ee (>82%) from the parent sulfide. Single recrystallizations afforded chiral fenthion sulfoxides with >99% ee, measured by chiral HPLC analysis. The absolute configuration of the (+)-sulfoxide generated from fenthion metabolism by FMO1 was determined to be (R)-(+)-fenthion sulfoxide, confirmed by X-ray crystallographic analysis of the (S)-(-)-antipode. Inhibition of human recombinant (hrAChE) and electric eel (eeAChE) acetylcholinesterase were assayed with fenthion, fenoxon, and the racemates and enantiomers of fenthion sulfoxide and fenoxon sulfoxide. Results revealed stereoselective inhibition with (R)-(+)-fenoxon sulfoxide when compared with that of (S)-(-)-fenoxon sulfoxide (IC50 of 6.9 and 6.5 microM vs 230 and 111 microM in hrAChE and eeAChE, respectively). Fenthion sulfoxide (R or S enantiomers) did not present anti-AChE properties. Although the stereoselective sulfoxidation of fenthion to (R)-(+)-fenthion sulfoxide by FMO represents a detoxification pathway, the results of this study support the notion that subsequent oxidative desulfuration of (R)-(+)-fenthion sulfoxide (in vivo) may represent a critical bioactivation pathway, resulting in the production of (R)-(+)-fenoxon sulfoxide, a potent AChE inhibitor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253727     DOI: 10.1021/tx060153l

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  6 in total

1.  Hypersalinity acclimation increases the toxicity of the insecticide phorate in coho salmon (Oncorhynchus kisutch).

Authors:  Ramon Lavado; Lindley A Maryoung; Daniel Schlenk
Journal:  Environ Sci Technol       Date:  2011-04-13       Impact factor: 9.028

2.  Microsomal biotransformation of chlorpyrifos, parathion and fenthion in rainbow trout (Oncorhynchus mykiss) and coho salmon (Oncorhynchus kisutch): mechanistic insights into interspecific differences in toxicity.

Authors:  Ramon Lavado; Daniel Schlenk
Journal:  Aquat Toxicol       Date:  2010-09-16       Impact factor: 4.964

Review 3.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

4.  Effects of salinity acclimation on the pesticide-metabolizing enzyme flavin-containing monooxygenase (FMO) in rainbow trout (Oncorhynchus mykiss).

Authors:  Ramon Lavado; Rosaura Aparicio-Fabre; Daniel Schlenk
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2012-09-06       Impact factor: 3.228

5.  Mechanisms of fenthion activation in rainbow trout (Oncorhynchus mykiss) acclimated to hypersaline environments.

Authors:  Ramon Lavado; John M Rimoldi; Daniel Schlenk
Journal:  Toxicol Appl Pharmacol       Date:  2008-12-09       Impact factor: 4.219

6.  The separation of several organophosphate pesticides on immobilized polysaccharide chiral stationary phases.

Authors:  William L Champion; William L Watts; Weston J Umstead
Journal:  Chirality       Date:  2022-05-31       Impact factor: 2.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.